Agalsidase Beta Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 35 mg
Reference Brands: Fabrazyme (USA/EU)
Category:
Orphan Drugs
Agalsidase beta is a recombinant form of the human enzyme alpha-galactosidase A, used in enzyme replacement therapy for Fabry disease. It helps break down globotriaosylceramide (GL-3), a fatty substance that accumulates in the cells of patients with this inherited lysosomal storage disorder. By reducing GL-3 buildup, Agalsidase beta helps alleviate symptoms such as pain, kidney dysfunction, and cardiovascular complications associated with Fabry disease.
Agalsidase beta is available in Injection
and strengths such as 35 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Agalsidase beta is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Agalsidase beta can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing